Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

The goal of osteoporosis management is to prevent fractures. Several pharmacological
agents are available to lower fracture risk, either by reducing bone resorption or by …

Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a
subclinical condition until complicated by fracture (s). These fractures place an enormous …

Abstract Summary The National Osteoporosis Guideline Group (NOGG) has revised the UK
guideline for the assessment and management of osteoporosis and the prevention of …

Osteoporosis is a skeletal disorder that causes impairment of bone structure and strength,
leading to a progressively increased risk of fragility fractures. The global prevalence of …

Objective The objective is to formulate clinical practice guidelines for the pharmacological
management of osteoporosis in postmenopausal women. Conclusions Evidence from …

Most women worldwide experience menopausal symptoms during the menopause transition
or postmenopause. Vasomotor symptoms are most pronounced during the first four to seven …

The adult bone is continuously being remodelled to repair microdamage, preserve bone
strength and mechanical competence as well as maintain calcium homeostasis. Bone …

PURPOSE To provide guidance regarding best practices in the prevention and
management of medication-related osteonecrosis of the jaw (MRONJ) in patients with …

Women spend approximately one-third of their lives with menopause, which occurs around
50 years of age. It is now appreciated that several important metabolic and cardiovascular …